Lilly reports on Oct. 29, and Zacks expects investors to focus on Foundayo after the oral GLP-1 brought in $98 million in its first full quarter on sale.
Recap by typeshit. Full story at TradingView.
The clinic says the choice should weigh long term outcomes and overall health, not just pounds lost, and that no single treatment fits everyone.
15:25
Doctor Alex says Ozempic works but comes with a catch, and walks through what he thinks people misunderstand about GLP-1 drugs.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
U of T researchers built the AI tool with the aim of speeding up how new peptide drugs are found. The university's announcement has the details.
Fractyl plans to file a De Novo request with the FDA in late Q4, yet its shares closed about 63% lower that day over a class action and doubts about 12-month results.
Loading…